DBV Technologies S.A.

NASDAQ:DBVT

Biotechnology

Healthcare
$9.99 -0.95%

-$0.16 today

Market cap
$238.98M
Beta
-0.22
P/E (TTM)
-8.3
EPS (TTM)
-$0.39
52W Low $8.50High $26.19

Volume 0.17M

Average 0.24M

DBVT Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

DBV Technologies S.A.NASDAQ: DBVT

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2023
-486.0%
Year-over-year change
+1527.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How DBVT compares with its peers on the latest reported figures

DBVT Competitors Peer median
Operating Margin for DBVT and competitors
Company Period LTM level YoY 3-year change
AMRNAmarin Corporation plcLTM Mar 2026-17.4% +27.0 pp+22.2 pp
CLLSCellectis S.A.LTM Mar 2026-67.6% +43.4 pp+422.4 pp
KRROKorro Bio, Inc.LTM Mar 2026-2154.0% -173.6 pp—
ALTAltimmune, Inc.LTM Mar 2026-269216.7% +221748.3 pp-359490.4 pp
DBVTDBV Technologies S.A.FY2025— ——
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
ANNXAnnexon, Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
ENGNenGene Holdings Inc.FY2025— ——
Peer median (excluding DBVT) -1110.8%+35.2 pp+22.2 pp

Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.71M4.8M15.73M00
Cost of Revenue9.27M20.3M06.81M17.67M
Gross Profit(3.57M)(15.5M)15.73M(6.81M)(17.67M)
Gross Margin-62.5%-322.9%100.0%——
Research & Development70.34M75.5M60.22M89.9M116.68M
Selling, General & Admin23.83M17.56M31.94M23.81M28.28M
Operating Expenses93.93M101.48M92.16M113.71M147.06M
Depreciation & Amortization8.38M20.3M13.16M6.81M7.73M
EBITDA(91.16M)(76.68M)(63.27M)(110.99M)(139.32M)
EBITDA Margin-1597.0%-1597.5%-402.3%——
Operating Income(98.61M)(96.63M)(76.43M)(120.53M)(147.06M)
Operating Margin-1727.6%-2013.1%-486.0%——
Interest Income521K406.29K3.71M2.73M601.86K
Interest Expense690K427K000
Other Income / Expenses424K427K3.71M2.73M600K
Income Before Tax(98.19M)(96.2M)(72.72M)(117.8M)(146.46M)
Pre-Tax Margin-1720.2%-2004.3%-462.4%——
Income Tax Expense(381K)70K7K(4.08M)491K
Net Income(97.81M)(96.3M)(72.73M)(113.72M)(146.95M)
Net Margin-1713.5%-2006.3%-462.4%——
EPS (Basic)(1.80)(1.25)(0.75)(1.20)(1.70)
EPS (Diluted)(1.80)(1.25)(0.75)(1.20)(1.70)
Weighted Avg Shares55.1M77.38M95.12M96.17M86.4M
Weighted Avg Shares (Diluted)55.1M77.38M95.12M96.17M86.4M

DBV Technologies S.A.

NASDAQ:DBVT

Intrinsic Alpha fair value

Locked

Current Price

$9.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.